Lee Te-An, Wang Shih-Han, Kuo Chun-Tse, Li Chia-Wei, McCullough Louise D, Bello Dhimiter, Lai Yun-Ju
Institute of Biomedical Sciences, Academia Sinica, Taipei 115, Taiwan.
Department of Neurology, McGovern Medical School, University of Texas Health Science Center at Houston, 6431 Fannin Street, Houston, TX, 77370, United States of America.
Transl Oncol. 2022 Jul;21:101443. doi: 10.1016/j.tranon.2022.101443. Epub 2022 May 2.
Cancer patients with COVID-19 likely express biomarker changes in circulation. However, the biomarkers used in SARS-CoV-2 infected cancer patients for COVID-19 severity and prognosis are largely unclear. Therefore, this systematic review aims to determine what biomarkers were measured in cancer patients with COVID-19 and their prognostic utility.
A systematic literature review in PubMed, Embase, and Scopus was performed on June 16th, 2021. The search keywords coronavirus, neoplasm, biomarkers, and disease progression were used to filter out 17 eligible studies, which were then carefully evaluated.
A total of 4,168 patients, 16 types of cancer, and 60 biomarkers were included. Seven up-regulated markers, including CRP, d-dimer, ferritin, IL-2R, IL-6, LDH, and PCT, were identified in eligible studies. Albumin and hemoglobin were significantly down-regulated in cancer patients with COVID-19. Moreover, we observed that the SARS-CoV-2 infected cancer patients with lower CRP, ferritin, and LDH levels successfully survived from COVID-19 treatments.
Several important clinical biomarkers, such as CRP, ferritin, and LDH, may serve as the prognostic markers to predict the outcomes following COVID-19 treatment and monitor the deterioration of COVID-19 in cancer patients.
新冠肺炎癌症患者可能会出现循环生物标志物变化。然而，用于评估感染新冠病毒的癌症患者的新冠肺炎严重程度和预后的生物标志物在很大程度上尚不清楚。因此，本系统评价旨在确定在新冠肺炎癌症患者中检测了哪些生物标志物及其预后效用。
于2021年6月16日在PubMed、Embase和Scopus数据库中进行了系统的文献综述。使用搜索关键词“冠状病毒”“肿瘤”“生物标志物”和“疾病进展”筛选出17项符合条件的研究，然后对其进行仔细评估。
共纳入4168例患者、16种癌症类型和60种生物标志物。在符合条件的研究中确定了7种上调标志物，包括CRP、D-二聚体、铁蛋白、IL-2R、IL-6、LDH和PCT。新冠肺炎癌症患者的白蛋白和血红蛋白显著下调。此外，我们观察到，新冠病毒感染的癌症患者中，CRP、铁蛋白和LDH水平较低者在新冠肺炎治疗后成功存活。
几种重要的临床生物标志物，如CRP、铁蛋白和LDH，可作为预后标志物，用于预测新冠肺炎治疗后的结果，并监测癌症患者新冠肺炎病情的恶化。
Zotero 插件
